- Home
- JSPR vs LTRN Comparison
JSPR vs LTRN Comparison
Compare JSPR & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JSPR | LTRN |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | 64 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7M | 31.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JSPR | LTRN |
|---|---|---|
| Price | $0.66 | $1.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $15.50 | ★ $25.00 |
| AVG Volume (30 Days) | 371.6K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.69 | $1.11 |
| 52 Week High | $7.19 | $5.74 |
Technical Indicators
Market Signals| Indicator | JSPR | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 16.03 | 34.21 |
| Support Level | N/A | $1.11 |
| Resistance Level | $1.44 | $3.79 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 1.60 | 35.50 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.